Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Open accessThe DOI matches its Crossref record; 105 of the 124 references it cites were found in a registry or an index.
Abstract
Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I (Topo I). The formation of a cleavable drug-Topo I-DNA complex results in lethal double-strand DNA breakage and cell death. However, de novo or acquired clinical resistance to camptothecins is common. Studies of the camptothecin analog irinotecan suggest the following general mechanisms of resistance: (i) variable levels of the enzymes involved in the conversion of irinotecan; (ii) reduced cellular accumulation from active drug efflux; (iii) reduced levels of Topo I expression; (iv) alterations in the structure of Topo I from different mutations; (v) alterations in the cellular response to camptothecin-Topo I-DNA complex formation, which involves proteasome degradation of Topo I and/or enhanced DNA repair; and (vi) activation of the transcription factor nuclear factor kappa B by DNA damage and subsequent suppression of apoptosis. Multiple approaches using pharmacological and biological modulation to circumvent the above mechanisms of resistance have been incorporated into ongoing clinical trials and are expected to enhance the antitumor activity of irinotecan and reduce its systemic toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Carboxylesterase 2 (CES2) is the critical enzyme for the activation of irinotecan, which can catalyze the conversion of irinotecan to the more active form of SN-38 (a topoisomerase inhibitor) [88].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [88]
In the citing paper
“In addition, the amount of TOP-1 bound to DNA is reduced, which may also lead to CRC resistance to irinotecan [88,131].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA
Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., & Hol, W. G. J. (1998) · Science · doi:10.1126/science.279.5356.1504 · Cited by 889
Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J., Juijn, J. A., Baas, F., & Borst, P. (1997) · PubMed · Cited by 882
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling
De Smaele, E., Zazzeroni, F., Papa, S., Nguyen, D. U., Jin, R., Jones, J., Cong, R., & Franzoso, G. (2001) · Nature · doi:10.1038/35104560 · Cited by 732
Inhibition of JNK activation through NF-κB target genes
Tang, G., Minemoto, Y., Dibling, B., Purcell, N. H., Li, Z., Karin, M., & Lin, A. (2001) · Nature · doi:10.1038/35104568 · Cited by 721
A Model for the Mechanism of Human Topoisomerase I
Stewart, L., Redinbo, M. R., Qiu, X., Hol, W. G. J., & Champoux, J. J. (1998) · Science · doi:10.1126/science.279.5356.1534 · Cited by 717
Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686
DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., & Potmesil, M. (1989) · Science · doi:10.1126/science.2555920 · Cited by 650
Houston, M. A., Abendroth, K., Baldwin, A. S., & Liu, R. (2001) · PubMed · doi:10.17615/k359-fr77 · Cited by 547
Requirement of NF-κB Activation to Suppress p53-Independent Apoptosis Induced by Oncogenic Ras
Mayo, M. W., Wang, C.-Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. W., Der, C. J., & Baldwin, A. S. (1997) · Science · doi:10.1126/science.278.5344.1812 · Cited by 533
Mechanism of Action of Camptothecin
Liu, L. F., Duann, P., Lin, C., D'Arpa, P., & Wu, J. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26375.x · Cited by 508
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
DNA topoisomerase-targeting antitumor drugs can be studied in yeast.
Nitiss, J., & Wang, J. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.20.7501 · Cited by 499
Chemoprevention of Colorectal Cancer
Jänne, P. A., & Mayer, R. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422606 · Cited by 496
Sulindac Inhibits Activation of the NF-κB Pathway
Yamamoto, Y., Yin, M.-J., Lin, K.-M., & Gaynor, R. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.27307 · Cited by 494
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 478
Mechanism of Action of Camptothecin
LIU, L. F., DESAI, S. D., LI, T., MAO, Y., SUN, M., & SIM, S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb07020.x · Cited by 476
Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., YOKOKURA, T., Sawada, S., Miyasaka, T., & Mutai, M. (1987) · PubMed · Cited by 410
Yeast Gene for a Tyr-DNA Phosphodiesterase that Repairs Topoisomerase I Complexes
Pouliot, J. J., Yao, K. C., Robertson, C. A., & Nash, H. A. (1999) · Science · doi:10.1126/science.286.5439.552 · Cited by 382
Biology of the multidrug resistance-associated protein, MRP
Loe, D. W., Deeley, R. G., & Cole, S. P. C. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00046-9 · Cited by 367
Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1516 · Cited by 357
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse, R. A., Lohrbach, K., Li, L., BOSRON, W. F., & Dolan, M. E. (2000) · PubMed · Cited by 353
Shao, R.-G. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1397 · Cited by 344
Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., & Kamataki, T. (1996) · PubMed · Cited by 336
Morris, E. J., & Geller, H. M. (1996) · The Journal of cell biology · doi:10.1083/jcb.134.3.757 · Cited by 306
Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., Compton, L. D., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15060-x · Cited by 302
Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
KANEDA, N., Nagata, H., Furuta, T., & YOKOKURA, T. (1990) · PubMed · Cited by 291
Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin
Desai, S. D., Liu, L. F., Vazquez-Abad, D., & D'Arpa, P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24159 · Cited by 269
Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer
Ilson, D. H., Saltz, L., Enzinger, P., Huang, Y., Kornblith, A., Gollub, M., O'Reilly, E., Schwartz, G., DeGroff, J., Gonzalez, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3270 · Cited by 268
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
Shah, S. A., Potter, M. W., McDade, T. P., Ricciardi, R., Perugini, R. A., Elliott, P. J., Adams, J., & Callery, M. P. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1150 · Cited by 260
Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S. I., Ono, M., & Kuwano, M. (1997) · PubMed · Cited by 249
Husain, I., Mohler, J. L., Seigler, H. F., & Besterman, J. M. (1994) · PubMed · Cited by 244
Maliepaard, M., van Gastelen, M. A., Tohgo, A., Hausheer, F. H., van Waardenburg, R. C. A. M., de Jong, L. A., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2001) · PubMed · Cited by 231
Effects of CPT‐11 in combination with other anti‐cancer agents in culture
Kano, Y., Suzuki, K., Akutsu, M., Suda, K., Indue, Y., Yosnida, M., Sakamoto, S., & Miura, Y. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500420 · Cited by 219
Desai, S. D., Li, T., Rodriguez-Bauman, A., Rubin, E. H., & Liu, L. F. (2001) · PubMed · Cited by 219
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos, A., Zanetta, S., Cresteil, T., Deroussent, A., Pein, F. J. L., Raymond, É., Vernillet, L., Risse, M., Boige, V., Gouyette, A., et al. (2000) · PubMed · Cited by 213
Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., & Cvitkovic, E. (1997) · Annals of Oncology · doi:10.1023/a:1008261821434 · Cited by 213
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Kehrer, D. F. S., Sparreboom, A., Verweij, J., de Bruijn, P., Nierop, C. A., van de Schraaf, J., Ruijgrok, E. J., & de Jonge, M. J. (2001) · PubMed · Cited by 176
Tan, K. B., Mattern, M. R., Eng, W.-K., McCabe, F. L., & Johnson, R. K. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.22.1732 · Cited by 171
Cusack, J. C., Liu, R., & Baldwin, A. S. (2000) · PubMed · Cited by 160
NF-κB Activation by Camptothecin
Huang, T. T., Wuerzberger-Davis, S. M., Seufzer, B. J., Shumway, S. D., Kurama, T., Boothman, D. A., & Miyamoto, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9501 · Cited by 159
Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Khanna, R., Morton, C. L., Danks, M. K., & Potter, P. M. (2000) · PubMed · Cited by 158
Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y., & Pommier, Y. G. (1995) · PubMed · Cited by 151
Irinotecan (CPT-11): Recent Developments and Future Directions–Colorectal Cancer and Beyond
Rothenberg, M. L. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-66 · Cited by 146
Chen, Z., Furukawa, T., Sumizawa, T., Ono, K., Ueda, K., Seto, K., & Akiyama, S.-I. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23189-8 · Cited by 135
Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells
Piret, B., & Piette, J. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.21.4242 · Cited by 131
Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
Chu, X., Kato, Y., & Sugiyama, Y. (1997) · PubMed · Cited by 129
Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion
Ishii, K., Usui, S., Sugimura, Y., Yoshida, S., Hioki, T., Tatematsu, M., Yamamoto, H., & Hirano, K. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(200102)9999:9999<::aid-ijc1178>3.0.co;2-6 · Cited by 128
Gastrointestinal toxicity or irinotecan.
Hecht, J. R. (1998) · PubMed · Cited by 126
Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion
Ohe, Y., Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Kojima, A., Kunikane, H., Okamoto, H., Karato, A., Ohmatsu, H., et al. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.12.972 · Cited by 122
Mo, Y.-Y., Yu, Y., Shen, Z., & Beck, W. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108263200 · Cited by 115
Schellens, J. H. M., Maliepaard, M., Scheper, R. J., Scheffer, G. L., Jonker, J. W., Smit, J. W., Beijnen, J. H., & Schinkel, A. H. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb07037.x · Cited by 111
Inhibition of NF-κB sensitizes non–small cell lung cancer cells to chemotherapy-induced apoptosis
Jones, D. R., Broad, R. M., Madrid, L. V., Baldwin, A. S., & Mayo, M. W. (2000) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(00)01635-0 · Cited by 109
Bertrand, R., O'Connor, P. M., Kerrigan, D., & Pommier, Y. G. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90107-d · Cited by 108
Burke, T. G., Munshi, C. B., Mi, Z., & Jiang, Y. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600840426 · Cited by 105
Modulation of DNA Topoisomerase I Activity by p53
Gobert, C., Bracco, L. P., Rossi, F., Olivier, M., Tazi, J., Lavelle, F., Larsen, A. K., & Riou, J. (1996) · Biochemistry · doi:10.1021/bi952327w · Cited by 102
Atsumi, R., Suzuki, W., & Hakusui, H. (1991) · Xenobiotica · doi:10.3109/00498259109039556 · Cited by 101
Whitacre, C. M., Zborowska, E., Gordon, N. H., Mackay, W., & Berger, N. A. (1997) · PubMed · Cited by 99
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Innocenti, F., Iyer, L., & Ratain, M. J. (2001) · PubMed · Cited by 98
Determinants of CPT-11 and SN-38 activities in human lung cancer cells
van Ark-Otte, J., Kedde, M., van der Vijgh, W., Dingemans, A. C., Jansen, W., Pinedo, H. M., Boven, E., & Giaccone, G. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.362 · Cited by 96
Gupta, E., Wang, X., Ramı́rez, J., & Ratain, M. J. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050595 · Cited by 95
Bentires‐Alj, M., Hellin, A., Ameyar‐Zazoua, M., Chouaïb, S., Merville, M. P., & Bours, V. (1999) · PubMed · Cited by 92
Chu, X., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E., et al. (1998) · PubMed · Cited by 90
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin, E. H., Wood, V., Bharti, A. K., Trites, D. H., Lynch, C., Hurwitz, S. J., Bartel, S. B., Levy, S., Rosowsky, A., & Toppmeyer, D. (1995) · PubMed · Cited by 87
Active Efflux of CPT-11 and Its Metabolites in Human KB-Derived Cell Lines
Chu, X., Suzuki, H., Ueda, K., Kato, Y., Akiyama, S., & Sugiyama, Y. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38014-0 · Cited by 86
Höchster, H. S., Wadler, S., Runowicz, C. D., Liebes, L., Cohen, H. W., Wallach, R. C., Sorich, J., Taubes, B., & Speyer, J. L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2553 · Cited by 84
Kojima, A., Hackett, N. R., Ohwada, A., & Crystal, R. G. (1998) · Journal of Clinical Investigation · doi:10.1172/jci119888 · Cited by 82
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
Gupta, E., Safa, A. R., Wang, X., & Ratain, M. J. (1996) · PubMed · Cited by 75
pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
Kobayashi, K., Bouscarel, B. E., Matsuzaki, Y., Ceryak, S. M., Kudoh, S., & Fromm, H. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991112)83:4<491::aid-ijc10>3.0.co;2-m · Cited by 72
Danks, M. K., Garrett, K. E., Marion, R. C., & Whipple, D. O. (1996) · PubMed · Cited by 69
Akimoto, K., KAWAI, A., & Ohya, K. (1994) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.42.2135 · Cited by 63
Mechanisms of Resistance to Camptothecins
Saleem, A., EDWARDS, T. K., Rasheed, Z. A., & Rubin, E. H. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb07024.x · Cited by 60
Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Ikegami, T., Ha, L., Arimori, K., Latham, P. S., Kobayashi, K., Ceryak, S. M., Matsuzaki, Y., & Bouscarel, B. E. (2002) · PubMed · Cited by 57
Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs
Reid, R. J. D., Benedetti, P., & Bjornsti, M. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00142-0 · Cited by 57
The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitro
Takahashi, T., Fujiwara, Y., Yamakido, M., Katoh, O., Watanabe, H., & Mackenzie, P. I. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00351.x · Cited by 54
Irinotecan and thalidomide in metastatic colorectal cancer.
Govindarajan, R. (2000) · PubMed · Cited by 51
Hammond, L. A., Eckardt, J. R., Ganapathi, R. N., Burris, H. A., Rodriguez, G. A., Eckhardt, S. G., Rothenberg, M. L., Weiss, G. R., Kuhn, J. G., Hodges, S., et al. (1998) · PubMed · Cited by 50
Höchster, H. S., Liebes, L., Speyer, J. L., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Blum, R. H., & Zeleniuch‐Jacquotte, A. (1997) · PubMed · Cited by 48
Tabata, M., Tabata, R., Grabowski, D., Bukowski, R. M., Ganapathi, M. K., & Ganapathi, R. N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009831200 · Cited by 46
Beidler, D. R., Chang, J., Zhou, B., & Cheng, Y. C. (1996) · PubMed · Cited by 45
Kojima, A., Hackett, N. R., & Crystal, R. G. (1998) · PubMed · Cited by 43
Jagasia, M., Langer, C. J., Johnson, D. H., Yunus, F., Rodgers, J. S., Schlabach, L., Cohen, A. G., Shyr, Y., Carbone, D. P., & DeVore, R. F. (2001) · PubMed · Cited by 41
Cellular Resistance to Topoisomerase Poisons
Rubin, E. H., Li, T., Duann, P., & Liu, L. F. (1996) · Cancer treatment and research · doi:10.1007/978-1-4613-1267-3_10 · Cited by 39
Meck, M. M., Wierdl, M., Wagner, L. M., Burger, R. A., Guichard, S. M., Krull, E. J., Harris, L. C., Potter, P. M., & Danks, M. K. (2001) · PubMed · Cited by 29
Elevations of DNA Topoisomerase I in Invasive Carcinoma of the Breast
Lynch, B. J., Bronstein, I. B., & Holden, J. A. (2001) · The Breast Journal · doi:10.1046/j.1524-4741.2001.007003176.x · Cited by 22
Expression of DNA topoisomerase I and DNAtopoisomerase II-Alpha in testicular seminomas
Coleman, L. W., PERKINS, S., Bronstein, I. B., & Holden, J. A. (2000) · Human Pathology · doi:10.1053/hupa.2000.8462 · Cited by 22
LI, X., HALUSKA, P., HSIANG, Y., BHARTI, A., KUFE, D. W., & RUBIN, E. H. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26381.x · Cited by 21
Shinohara, H., Killion, J. J., Bucana, C. D., Yano, S., & Fidler, I. J. (1999) · PubMed · Cited by 18
Murren, J. R., Beidler, D. R., & Cheng, Y. C. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26378.x · Cited by 17
Riou, J., Grondard, L., Petitgenet, O., Abitbol, M. M., & Lavelle, F. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90494-h · Cited by 8
Mori, K., Hirose, T., Machida, S., & Tominaga, K. (1998) · PubMed · Cited by 5
Shida, A., Ohtsuka, K., Jin, M., Inoue, S., Kanetoshi, A., Fujimoto, T., Takaoka, K., Araya, Y., & Itoh, M. (1997) · Lung Cancer · doi:10.1016/s0169-5002(97)89371-3 · Cited by 4
Research works printed but not linked: 8
- Ilson, 1999, Phase II trial of weekly irinotecan + cisplatin in advanced gastric cancer, Proc Am Soc Clin Oncol, 18, 259a
- Hecht, 1998, Gastrointestinal toxicity of irinotecan, Oncology, 12, 72
- Prados, 2001, A phase-I study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma A North American Brain Tumor Consortium (NABTC) study, Proc Am Soc Clin Oncol, 19, 162
- Kameyama, 2000, Activation and detoxification of CPT-11 by human lung cancer cells, Proc Am Soc Clin Oncol, 19, 505a
- Villalona-Calero, 2001, Pharmacologically-based phase I study of mitomycin C (MMC) as a modulator of irinotecan (CPT-11) antitumor activity, Proc Am Soc Clin Oncol, 20, 101a
- Kolesar, 2002, TI induction in PBMC by mitomycin-C predicts irinotecan response, Proc Am Soc Clin Oncol, 21, 115
- Ratain, 1999, A phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB), Proc Am Soc Clin Oncol, 18, 202a
- Takeda, 2001, Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients, Int J Cancer, 92, 269, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1179>3.0.CO;2-3 · DOI
Cited by
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660
The challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 600
Metadata
- Authors
- Xu, Y., & Villalona-Calero, M. A.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Corresponding author
- Villalona-Calero, M.A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2002-12
- Volume
- 13
- Issue
- 12
- Pages
- 1841-1851
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2112055293
- Cited by
- 413
- References
- 124
- Citations by year
- 2026: 25 · 2025: 18 · 2024: 25 · 2023: 40 · 2022: 30 · 2021: 23 · 2020: 24 · 2019: 17 · 2018: 16 · 2017: 22 · 2016: 15 · 2015: 24 · 2014: 13 · 2013: 11 · 2012: 10
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 6246 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas Health Science Center at San Antonio
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, camptothecin, topoisomerase I, drug resistance, drug efflux, proteasomal degradation, DNA repair, NF-κB, apoptosis, anticancer drug metabolism, combination therapy
- MeSH terms
- Irinotecan, Animals, Camptothecin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Neoplasms, Sensitivity and Specificity, NF-kappa B, Apoptosis, Risk Assessment, Drug Resistance, Neoplasm, Maximum Tolerated Dose, Topoisomerase I Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.